Irene A. George , Richa Chauhan , R.E. Dhawale , Roshini Iyer , Sewanti Limaye , R. Sankaranarayanan , R. Venkataramanan , Prashant Kumar
{"title":"癌症治疗耐药性的探讨","authors":"Irene A. George , Richa Chauhan , R.E. Dhawale , Roshini Iyer , Sewanti Limaye , R. Sankaranarayanan , R. Venkataramanan , Prashant Kumar","doi":"10.1016/j.adcanc.2022.100074","DOIUrl":null,"url":null,"abstract":"<div><p>Treatment failure is one of the main hurdles in treating cervical cancer, despite significant breakthroughs in both conventional and targeted therapy. The one-year survival of patients with advanced or recurrent cervical cancer globally is less than 30%. Chemotherapy, radiation, and concurrent chemoradiotherapy are among the therapeutic modalities being used in clinics, depending on the stage of the disease. However, resistance to these treatment methods compromises the efficacy of the overall treatment. Numerous approaches based on prognostic biomarkers and combination therapy with multiple agents may be able to successfully combat treatment resistance in cervical cancer. In this review, we discuss the molecular mechanisms of treatment resistance in cervical cancer.</p></div>","PeriodicalId":72083,"journal":{"name":"Advances in cancer biology - metastasis","volume":"6 ","pages":"Article 100074"},"PeriodicalIF":2.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266739402200048X/pdfft?md5=8b12c0d956b1d899e64faa0860b9f928&pid=1-s2.0-S266739402200048X-main.pdf","citationCount":"5","resultStr":"{\"title\":\"Insights into therapy resistance in cervical cancer\",\"authors\":\"Irene A. George , Richa Chauhan , R.E. Dhawale , Roshini Iyer , Sewanti Limaye , R. Sankaranarayanan , R. Venkataramanan , Prashant Kumar\",\"doi\":\"10.1016/j.adcanc.2022.100074\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Treatment failure is one of the main hurdles in treating cervical cancer, despite significant breakthroughs in both conventional and targeted therapy. The one-year survival of patients with advanced or recurrent cervical cancer globally is less than 30%. Chemotherapy, radiation, and concurrent chemoradiotherapy are among the therapeutic modalities being used in clinics, depending on the stage of the disease. However, resistance to these treatment methods compromises the efficacy of the overall treatment. Numerous approaches based on prognostic biomarkers and combination therapy with multiple agents may be able to successfully combat treatment resistance in cervical cancer. In this review, we discuss the molecular mechanisms of treatment resistance in cervical cancer.</p></div>\",\"PeriodicalId\":72083,\"journal\":{\"name\":\"Advances in cancer biology - metastasis\",\"volume\":\"6 \",\"pages\":\"Article 100074\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S266739402200048X/pdfft?md5=8b12c0d956b1d899e64faa0860b9f928&pid=1-s2.0-S266739402200048X-main.pdf\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cancer biology - metastasis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266739402200048X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cancer biology - metastasis","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266739402200048X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Insights into therapy resistance in cervical cancer
Treatment failure is one of the main hurdles in treating cervical cancer, despite significant breakthroughs in both conventional and targeted therapy. The one-year survival of patients with advanced or recurrent cervical cancer globally is less than 30%. Chemotherapy, radiation, and concurrent chemoradiotherapy are among the therapeutic modalities being used in clinics, depending on the stage of the disease. However, resistance to these treatment methods compromises the efficacy of the overall treatment. Numerous approaches based on prognostic biomarkers and combination therapy with multiple agents may be able to successfully combat treatment resistance in cervical cancer. In this review, we discuss the molecular mechanisms of treatment resistance in cervical cancer.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
